Alynlam Pharmaceuticals and The Medicines Company reported positive initial results from their ongoing Phase 1 clinical trial with their injectable cholesterol-lowing drug, ALSN-PCSsc, at the ESC Congress 2015 held in London, August 29 – September 2.
Healthcare providers, celebrities, patients and others are helping to increase awareness of idiopathic pulmonary fibrosis (IPF) during the Pulmonary Fibrosis Foundation’s (PFF) Pulmonary Fibrosis Awareness Month.
Over the last 10 years, Blue Cross Blue Shield of Michigan and stakeholders have prevented $1.4 billion in health expenses. Here's how.
The next stage of chronic care management and value-based insurance design for the continuing onslaught of high-priced specialty drugs, including PCSK9 inhibitors.
Pre-exposure prophylaxis (PrEP) may prevent HIV infection, according to a study published in Clinical Infectious Diseases. It is one of the first and largest published evaluations of the use of PrEP to prevent HIV infection in a clinical practice setting.
FDA has approved rolapitant (Varubi, Tesaro) for the prevention of chemotherapy-induced nausea and vomiting.
Rituxan (rituximab) has a consistent safety profile through multiple courses over 11 years of observation, according to a new long-term study published in the online edition of The Journal of Rheumatology.
In this commentary, attorney Nathaniel Lacktman shares why, in the era of payment reform, it is critical for health plans to provide telemedicine reimbursement.
Telemedicine is moving from a new trend to a respected form of care delivery. Here's how it is changing, and how reimbursement is evolving.
Here are seven ways to attract more millennials to your business.
The first biosimilar drug approved by FDA in March was officially launched in the United States on September 3 – at a value compared to competing medications.
A medical group in New York is rapidly shifting toward “value-based” care from fee-for-service (FFS)-spurred on by a program to reduce variations in physician practice that began by focusing on patients with diabetes.
FDA warned this week that several leading drugs for type 2 diabetes may cause severe and disabling joint pain. FDA said that sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain, and added a new Warning and Precaution about this risk to the labels of all dipeptidyl peptidase-4 (DPP-4) inhibitors.
Experts explain why more plans are getting involved in private exchanges, and share recommendations for what to do about it.
Industry experts weigh the options between a traditional pharmacy benefits manager and a pharmacy benefits administrator.
Americans are spending more time evaluating their insurance options, and more Americans are considering different sources.
The high cost of these medications could overwhelm patients and plans, according to one expert.
The Academy of Managed Care Pharmacy (AMCP) is opposing Ohio House Bill 248, because it believes the bill would mandate coverage of abuse-deterrent opioid analgesic drug products “without regard to the balance between the unique and varied needs of individual patients.”
IIn a new long-term study, nintedanib (Ofev) improved forced vital capacity (FVC) and other idiopathic pulmonary fibrosis (IPF) symptoms. The findings were presented recently at the American Thoracic Society (ATS) 2015 International Conference in Denver.
Pharmacies should be wary of potential drug name changes that could occur if FDA finalizes its new draft guidance on biosimilar naming, which proposes proper names for biosimilars.
Decades of research shows that brainstorming doesn’t work when attempting to solve difficult problems. Here's what healthcare leaders should do instead.
The inability to coordinate care for these seniors leads to more health problems, and higher costs.
A health kiosk-decision support system may be a novel and important approach to improve provider prescription patterns.
The impact of the reemergence of untreatable infections on our healthcare costs could be prohibitive. Find out what's being done about it.
Among the most significant changes today is the transformation of patients to health consumers. Here's how plans and providers should adapt.
Program aims to prevent drug diversion
FDA has approved empagliflozin and metformin hydrochloride (Synjardy, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company) tablets for the treatment of adults with type 2 diabetes.
FDA has expanded approval of eltrombopag (Promacta, Novartis) to treat low blood platelet count in pediatric patients with chronic immune thrombocytopenic purpura.
Fortune describes the 5 fastest-growing US pharmaceutical manufacturers.
The drop in the number of uninsured may seem like a good thing, but managed care executives need to be on guard in three areas.